Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00645775 |
Recruitment Status :
Completed
First Posted : March 28, 2008
Last Update Posted : March 28, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome Obesity Dyslipidemia | Dietary Supplement: IGOB131 | Not Applicable |
To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.
The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.
Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 102 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon. |
Study Start Date : | November 2006 |
Actual Primary Completion Date : | March 2007 |
Actual Study Completion Date : | April 2007 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: 1
Compare active to placebo
|
Dietary Supplement: IGOB131
Comparison of 250 mg per day of Irvingia gabonensis to placebo |
- Weight change [ Time Frame: 10 weeks ]
- Change in blood lipids and hormone levels [ Time Frame: 10 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- BMI>26
Exclusion Criteria:
- Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00645775
Cameroon | |
Laboratory of Nutrition & Nutritional Biochemistry | |
Yaounde, Centre, Cameroon, BP812 |
Study Director: | Julius E Oben, PhD | Gateway Health Alliances / University of Yaounde |
Responsible Party: | Pr. Julius Oben, CSO, Gateway Health Alliances |
ClinicalTrials.gov Identifier: | NCT00645775 |
Other Study ID Numbers: |
GHAIGOB131CT |
First Posted: | March 28, 2008 Key Record Dates |
Last Update Posted: | March 28, 2008 |
Last Verified: | August 2006 |
Weight loss Antiobesity Metabolic syndrome Leptin |
Obesity Metabolic Syndrome Dyslipidemias Syndrome Disease Pathologic Processes Overnutrition Nutrition Disorders |
Overweight Body Weight Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Lipid Metabolism Disorders |